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Abstract: Clinically relevant exocytosis of mast cell (MC) mediators can be triggered by high-affinity
IgE receptor (FcεRI)-aggregation (allergic route) or by the so-called pseudo-allergic pathway elicited
via MAS-related G protein-coupled receptor-X2 (MRGPRX2). The latter is activated by drugs and
endogenous neuropeptides. We recently reported that FcεRI-triggered degranulation is attenuated
when human skin mast cells are chronically exposed to IL-33. Here, we were interested in the
regulation of the MRGPRX2-route. Chronic exposure of skin MCs to IL-33 basically eliminated the
pseudo-allergic/neurogenic route as a result of massive MRGPRX2 reduction. This downregulation
seemed to partially require c-Jun N-terminal Kinase (JNK), but not p38, the two kinases activated by
IL-33 in skin MCs. Surprisingly, however, JNK had a positive effect on MRGPRX2 expression in the
absence of IL-33. This was evidenced by Accell®-mediated JNK knockdown and JNK inhibition. In
stark contrast to the dampening effect upon prolonged exposure, IL-33 was able to prime for increased
degranulation by MRGPRX2 ligands when administered directly before stimulation. This supportive
effect depended on p38, but not on JNK activity. Our data reinforce the concept that exposure length
dictates whether IL-33 will enhance or attenuate secretion. IL-33 is, thus, the first factor to acutely
enhance MRGPRX2-triggered degranulation. Finally, we reveal that p38, rarely associated with MC
degranulation, can positively affect exocytosis in a context-dependent manner.
Keywords: mast cells; skin; IL-33; pseudo-allergy; neurogenic mast cell activation; neuropeptides;
MRGPRX2; degranulation; JNK; p38
1. Introduction
MAS-related G protein-coupled receptor-X2 (MRGPRX2) has become a recent focus in mast cell
(MC) research. The G-protein coupled receptor triggers so-called pseudo-allergic and neurogenic
reactions by degranulating MCs independently of the classical FcεRI-mediated allergic route, but
the ensuing symptoms clinically phenocopy those arising from allergic MC stimulation [1–4]. The
discovery of MRGPRX2 and its murine equivalent Mrgprb2 marks a paradigm change in MC biology [5]
and can now explain observations that remained inexplicable in the past, including the divergent
response patterns among MCs from different tissues to basic secretagogues and neuropeptides [6,7].
In fact, depending on the content of secretory granules, human MCs are categorized into two
subtypes [8]. Most lung and gut MCs belong to the so-called MCT category and express only tryptase,
while most connective tissue MCs are of the MCTC type, characterized by the presence of tryptase and
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chymase, and some other characteristics [9,10]. MCT roughly correspond to MMC (mucosal MCs)
in the mouse, whereas the murine correlate of MCTC is the CTMC subset (connective tissue type
MCs) [1,5].
Interestingly, MRGPRX2 (or its murine equivalent Mrgprb2) is highly expressed in the
MCTC/CTMC subsets, whereas MCT/MMC-type MCs lack the receptor [5,11–13]. This expression
pattern now makes clear why the latter types are refractory to secretagogues like compound 48/80 and
Substance P (SP), which have been used to activate human skin MCs (nearly all MCTC) and rodent
CTMC for decades without knowing the receptor and mechanism involved [6,7].
The clinical importance of MRGPRX2 is underlined by the plethora of endogenous and exogenous
ligands, which trigger its activation. They comprise antimicrobial host defense peptides (e.g.,
cathelicidin), neuropeptides (including SP and somatostatin), and various FDA-approved cationic
drugs known to trigger pseudo-allergic reactions in susceptible individuals [1,11,14,15]. We recently
reported that the allergic and pseudo-allergic/neurogenic degranulation routes are independently
controlled at the population level [16]. This was in accordance with the two patterns of granule
exocytosis, as described by Gaudenzio and colleagues [17]. In their study, MRGPRX2-mediated
degranulation was a rapid process, associated with a quick and transient peak of Ca2+ influx, followed
by secretion of individual granules, whereas FcεRI-elicited secretion was delayed, but progressive, and
characterized by granule-to-granule fusion, also termed compound exocytosis [17].
Surprisingly, we also observed that MRGPRX2- and FcεRI-triggered activation routes are inversely
regulated by stem cell factor (SCF) [16], the most crucial supportive factor of the MC lineage [18]. In
our studies, SCF did not only attenuate pseudo-allergic/neurogenic responses when provided acutely
to skin MCs, i.e., directly before stimulation, but it also dampened MRGPRX2 expression and function
during skin MC culture, where it co-operated with IL-4 to inhibit the alternative route [19]. Skin MCs
exposed to retinoic acid likewise diminished MRGPRX2 function [20]. Conversely, the allergic route
was simultaneously promoted by all of the above stimuli, i.e., SCF, IL-4, and retinoic acid [19,20].
IL-33 is another cytokine crucially implicated in MC biology [21–23]. We recently reported that
chronic exposure of human skin MCs to IL-33 dampens their ability to respond to FcεRI aggregation [24].
Because others had reported that IL-33 boosted allergic degranulation when given acutely [25–28]
but led to lowered secretion after long-term exposure [29], the combined data indicated a dichotomy
between short and persistent contact with the cytokine.
In the current study, we examined the role of IL-33 in the context of MRGPRX2-triggered
activation of skin MCs. We report that long-term contact with IL-33 virtually eliminates expression
of MRGPRX2 and therefore erases MC responsiveness to MRGPRX2 ligands. In stark contrast, a
short burst of IL-33 primes the pseudo-allergic/neurogenic (and also the allergic) route, and this
enhancement occurs in a p38-dependent manner. The current data further emphasize the double-edged
character of IL-33 in skin MC biology. They also reveal IL-33 as the first factor described to date to
positively influence the MRGPRX2 cascade in skin MCs and to act congruently on the allergic and
pseudo-allergic/neurogenic routes.
2. Materials and Methods
2.1. Isolation and Culture of Human Skin MCs
MCs were obtained from human foreskin and breast skin tissue by a routinely employed
technique [13,20,30–33]. Human skin tissue was obtained from circumcisions or cosmetic breast
reduction surgeries, with informed consent provided by the patients or their legal guardians and
approval by the university ethics committee. The experiments were performed according to the
Declaration of Helsinki Principles. Breast skin samples were from single donors, while foreskins
were pooled from several donors (typically 2–9) and used as one preparation to obtain the required
cell numbers.
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The skin was cut into strips and treated at 4 ◦C overnight with 0.5 mg/mL dispase (BD Biosciences,
Heidelberg, Germany). The epidermis was removed, and the dermis was smashed and digested
with 150 mg/mL collagenase (Worthington, Lakewood, NJ, USA), 75 mg/mL hyaluronidase (Sigma,
Deisenhofen, Germany), and DNase I at 10 µg/mL (Roche, Basel, Switzerland) at 37 ◦C in a shaking
water bath for 1 h. The cells were filtered from remaining tissue. MC purification was achieved
with anti-human c-Kit microbeads and the Auto-MACS separation device (both from Miltenyi-Biotec,
Bergisch Gladbach, Germany). MC purity, as assessed by acidic toluidine-blue staining, was >98%.
Viability by trypan blue exclusion was >99%.
2.2. MC Treatment
For long-term culture experiments, mostly breast skin-derived MCs were kept in SCF alone
(100 ng/mL) or SCF and IL-33 (20 ng/mL) for 5 weeks, exactly as described [24]. Cytokines were provided
once a week and cultures were automatically counted (by CASY-TTC, Innovatis/Casy Technology,
Reutlingen, Germany) [30–33] and re-adjusted to 5 × 105/mL on a weekly basis. Two preparations of
foreskin MCs were used for 5-week cultures analogously to breast skin MCs (Figure S1).
For the other experiments, mainly foreskin MCs were used upon reaching optimal proliferation
with SCF (100 ng/mL) and IL-4 (20 ng/mL) or SCF alone [13,33,34]. Cells were deprived of cytokines
for 16 h prior to downstream experiments. For priming experiments, cells were pretreated with no
additive or IL-33 (20 ng/mL) for 30 min. For kinase inhibition, cells were pre-incubated with SP600125
(JNK inhibitor, 5 µM) or SB203580 (p38 inhibitor, 5 µM) for 15 min (both from ApexBio, Houston, TX,
USA) prior to the addition of IL-33 (i.e., 45 min prior to the stimulus).
2.3. Accell®-Mediated RNA Interference
RNA interference in MCs was performed according to an established protocol [24,35,36] using
the Accell® siRNA technology (Dharmacon, Lafayette, CO, USA). Briefly, MCs were washed with 1 ×
Accell siRNA medium (supplemented with Non-Essential Amino Acids and L-Glutamine), plated at
1 × 106/mL in Accell siRNA medium and treated with 1µM JNK-targeting siRNA (E-003514-00-0010)
or non-targeting siRNA (D-001910-10-50, serving as control) for 48 h. After incubation, cells were
treated with or without IL-33 for the times indicated.
2.4. Flow Cytometry
Flow-cytometry was performed according to routine protocols [30]. Briefly, MCs were blocked
for 15 min at 4 ◦C with human AB-serum (Biotest, Dreieich, Germany) and incubated with specific
antibodies for 30 min at 4 ◦C. The antibodies were as follows: 0.5 µg/mL of anti-human FcεRIα-FITC
(clone AER-37, eBioscience, San Diego, CA, USA), Mouse IgG2b, κ-FITC served as isotype control;
0.15 µg/mL PE-labelled anti-human MRGPRX2 (clone K12H4, Biolegend San Diego, CA, USA), mouse
IgG2b-PE (clone eBWG2b, eBioscience) served as isotype control. After washing, cells were measured
on the Facscalibur (BD Biosciences, San Jose, CA, USA) and analyzed with the FowJo analysis
software (FlowJo LLC, Ashland, OR, USA). Net mean fluorescence intensity (MFI), i.e., “MFI specific
antibody–MFI isotype control” served for receptor quantification. Negative values were set as 0.
2.5. Determination of Histamine Release
Histamine release assays were performed by a method routinely employed in our
laboratory [16,30–33]. In brief, cell suspensions were divided into aliquots, washed twice with
PAC-CM (piperazine-N,N′-bis[2-ethanesulfonic acid]-albumin-glucose buffer containing 3 mM CaCl2
and 1.5 mM MgCl2, pH 7.4), resuspended, and challenged at 1× 105/mL by compound 48/80 (10 µg/mL),
SP (30 µmol/L), or no stimulus (spontaneous) for 30 min at 37 ◦C. Supernatants were collected by
centrifugation and stored at −20 ◦C. Complete cellular histamine content was assessed upon cell lysis
with 1% perchloric acid. Histamine in the supernatants and complete histamine were measured by an
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automated fluorescence method (Borgwaldt Technik, Germany, Hamburg). The net histamine release
(%) was calculated as [(stimulated release − spontaneous release)/complete histamine present in the
MC preparation] × 100.
2.6. β-Hexosaminidase Release Assay
Cell suspensions were washed twice and resuspended at 5 × 105 cells/mL in PAC-CM buffer.
Aliquots of 100 µL were seeded into 96-well plates and stimulated by FcεRI-aggregation (AER-37
at 0.1 µg/mL, compound 48/80 (10 µg/mL), SP (30 µmol/L), or kept in buffer only. After incubation
for 30 min, supernatants (SNs) were collected by centrifugation at 500× g, 4 ◦C for 3 min,
and the pelleted MCs rapidly frozen at −80 ◦C. After thawing, aliquots of 50 µL of 4-methyl
umbelliferyl-N-acetyl-beta-d-glucosaminide (Sigma-Aldrich, Munich, Germany) solution at 5 µM in
citrate buffer (pH 4.5) were mixed with the same volume of supernatant or lysate and incubated for
60 min at 37 ◦C to measure the level of secreted and cell-remaining β-hexosaminidase. The reaction
was stopped by adding 100 mM sodium carbonate buffer (pH 10). Optical density (OD) was measured
at 405 nm. Percent β-hexosaminidase release was calculated as: [OD SN/(OD SN + OD lysate)] × 100.
Net release was calculated by subtracting spontaneous release, as in the histamine release assay above.
2.7. Reverse Transcription-Quantitative PCR (RT-qPCR)
Total RNA was isolated using the RNeasy Total RNA Kit, digested with RNase free DNase
(Qiagen, Hilden, Germany), and PCR carried out with the LC Fast Start DNA Master SYBR Green
kit (Roche Applied Science). Primers for MRGPRX2 were 5′-GGATCAGGAAGACCGGGATCA and
5′-CGGCCTGGGGAACAGAAAGT. The values were normalized to the housekeeping genes β actin,
cyclophilin B, and GAPDH (Glyceraldehyde 3-phosphate dehydrogenase), each ratio contrasted against
control conditions (set as 1) and the mean of the three determinations was used for the analysis and is
depicted in the figures [30,31,33].
2.8. Immunoblot Analysis
Detection of JNK and p38 activation was performed exactly as described [24]. In brief, MCs
deprived of growth factors were stimulated with IL-33 (20 ng/mL) for 15 min or kept without
stimulus (control), then boiled in Laemmli buffer, and lysates resolved by SDS-PAGE (Sodium
Dodecyl Sulfate Polyacrylamide Gel Electrophoresis). After transfer to a blotting membrane and
incubation with antibodies, proteins were visualized by a chemiluminescence assay (Weststar Ultra
2.0, Cyanagen, Bologna, Italy) and bands recorded on a chemiluminescence imager (Fusion FX7
Spectra, Vilber Lourmat, Eberhardzell, Germany). The following primary antibodies from Cell
Signaling Technology (Frankfurt am Main, Germany) were used: Anti-p-p38 (Thr180/Tyr182, #9211),
anti-p38 (#9212), anti-p-JNK (T183/Y185, #9251), and anti-JNK (#9252). Bands were quantified by
densitometry with the software ImageJ (National Institutes of Health, Bethesda, MD, USA) and the
degree of phosphorylation was assessed by the following equation: Ratio of phosphorylated protein =
densityphospo-protein/densitytotal protein.
2.9. Statistics
For 2-sample comparisons, differences between groups were assessed by paired t-test or by
Wilcoxon matched-pairs signed rank test (when not normally distributed) or by one-sample t-test
(when normalized to control). For more than two groups, Kruskal–Wallis test (non-parametric ANOVA)
with Dunn′s multiple comparisons test was employed. Statistical analyses were performed with
GraphPad-Prism 7 (San Diego, CA, USA). p < 0.05 was considered as statistically significant.
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3. Results
3.1. Skin MCs Lose Responsiveness to MRGPRX2 Ligands and Massively Downregulate MRGPRX2
Expression after Long-Term Exposure to IL-33
Our previous study indicated that chronic exposure to IL-33 reduces FcεRI expression
and responsiveness to its aggregation [24]. To reveal an effect of IL-33 on the alternative
pseudo-allergic/neurogenic route, MRGPRX2-elicited degranulation was assessed after culture of
skin MCs in the presence of IL-33 for 5 weeks. Using breast-skin derived MCs, we found that
MRGPRX2-triggered degranulation was severely hampered by IL-33, as evidenced with an exogenous
and an endogenous ligand, respectively, i.e., compound 48/80 (C48/80) and SP (Figure 1a). The effect
was consistent and found for MCs from every single donor (Figure 1a).
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Figure 1. Chronic exposure to IL-33 abrogates MAS-related G protein-coupled receptor-X2
(MRGPRX2)-triggered degranulation through reduced receptor expression. Cells were cultured
in SCF only or SCF and IL-33 for five weeks. (a) Net histamine release elicited by C48/80 and SP (n = 11).
(b) MRGPRX2 relative mRNA expression (mean ± SEM, n = 15). (c,d) MRGPRX2 cell surface expression
determined by flow-cytometry. (c) Representative histograms, red: Isotype, blue: MRGPRX2-specific
antibody. (d) Cumulative data given as net mean fluorescence intensity (MFI) (MFI specific antibody
−MFI isotype control) ± SEM of four independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.0001.
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Addressing the reason behind this phenomenon, we detected that IL-33 curtailed MRGPRX2
expression, both at the mRNA (Figure 1b) and protein level (Figure 1c,d). In several MC preparations,
MRGPRX2 expression in IL-33-high surroundings was below detection, explaining their resistance to
MRGPRX2 ligands (Figure 1a). Foreskin MCs showed the same behavior on long-term culture with
IL-33 as breast skin MCs (Figure S1), implying that the effect was universal and independent of sex,
age, and precise skin site.
Collectively, long-term IL-33 diminishes MRGPRX2 expression and thereby restrains MC
responsiveness to its ligation.
3.2. IL-33-Triggered Downregulation of MRGPRX2 Is Partially JNK-Dependent, although JNK Is A Positive
Regulator of MRGPRX2 in the Absence of IL-33
We set out to address the mechanism beyond the notable downregulation of MRGPRX2. Because
the use of inhibitors for prolonged times (like five weeks) would have been impractical, we first
assessed with a time-course analysis after what time MRGPRX2 downregulation commenced following
the addition of IL-33. This approach revealed that the decrease at transcript level was rapid (detectable
at 2–4 h after the addition of IL-33) but still detectable at 48 h without re-addition of IL-33 (Figure S2).
The 4-h time point was selected for further experiments (and based on this, the 24 h point was chosen
for the analysis of protein expression). The rapid response to IL-33 made pharmacological interference
and knockdown experiments feasible without concerns about indirect effects (likely accumulating over
a five-week period and precluding proper interpretation).
We recently reported that among several signaling intermediates, JNK and p38 were the ones
activated by IL-33 in skin-derived MCs [24]. Here, we reproduced this pattern by demonstrating JNK
and p38 phosphorylation 15 min upon IL-33 administration (Figure S3).
To address the potential involvement of the two kinases in the regulation of MRGPRX2 by IL-33,
we employed selective inhibitors and Accell®-facilitated knockdown (KD). The latter strategy used
a recently established protocol which enables us to perturb endogenous levels of proteins in tissue
MCs [24,36].
Surprisingly, we found that the JNK inhibitor alone (but not the p38 inhibitor) dampened
MRGPRX2 expression (Figure 2a,b). This was duplicated by RNAi-mediated JNK-KD (Figure 2c,d,
for knockdown efficiency see Figure S4). Considering this baseline effect of JNK interference on the
expression of MRGPRX2, we wondered whether reduced JNK function and IL-33 would give additive
effects when applied to cells together. However, this was not the case, as their combined application
did not further reduce MRGPRX2 vis-à-vis each treatment alone. Conversely, inhibition of JNK in the
context of IL-33 resulted in higher MRGPRX2 expression (compared to JNK perturbation alone) both at
the protein and mRNA level, while the inhibition of p38 had no effect (Figure 3a,b). The same tendency
was found for JNK-specific siRNA, i.e., a slight reversal in MRGPRX2 downregulation by IL-33 could
be noted, although the extent was lesser compared to the JNK inhibitor (Figure 3). Notwithstanding,
with all combinations of strategies and readouts, the ratio “with IL-33/without IL-33” was enhanced
after interference with JNK, meaning that JNK perturbation in the presence of IL-33 slightly rescued
MRGPRX2 versus the same treatment in its absence. Note that regulation of MRGPRX2 at the transcript
level was typically more pronounced than that of the respective protein but that both processes were
consistent in their direction.
We conclude that JNK triggered by IL-33 is partially responsible for the attenuated expression
of MRGPRX2 in IL-33-rich surroundings. Paradoxically however, in the absence of IL-33, JNK helps
maintain MRGPRX2 expression.
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Figure 3. Perturbation of JNK function partially reverses the negative effect of IL-33 on MRGPRX2
expression. (a,b) After deprivation of growth factors overnight, cells were pretreated with the inhibitor
SB203580 (p38) or SP600125 (JNK) for 15 min, followed by IL-33 stimulation. Cells treated with
inhibitors alone served as controls. All data are presented as ratios “IL-33/no IL-33” (mean ± SEM) as in
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our recent publication [24]. (a) After 4 h, cells were harvested for MRGPRX2 mRNA, as determined by
RT-qPCR (n = 7). (b) After 24 h, MRGPRX2 cell surface expression was determined by flow-cytometry
(n = 16). (c,d) Cells pre-exposed to JNK-siRNA or control siRNA for 48 h were stimulated with IL-33 or
left untreated. (c) RNA was taken after an additional 4 h, and MRGPRX2 mRNA expression quantified
by RT-qPCR. (d) MRGPRX2 protein expression was measured after 24 h. For the effects of JNK-siRNA
alone, see Figure 2. Data are the mean ± SEM of five to seven independent experiments. * p < 0.05,
*** p < 0.001.
3.3. Short-Term Priming by IL-33 Fosters Skin MC Degranulation
Having found that IL-33 was a potent negative regulator of MRGPRX2 function through restrained
expression, we asked whether IL-33 may influence MC degranulation acutely (i.e., after short
preincubation). By applying the endogenous MRGPPRX2 ligand SP or the exogenous secretagogue
C48/80 [4,5,37], we found that IL-33 indeed augmented secretion triggered by both ligands (Figure 4a,b).
In addition, degranulation elicited by FcεRI aggregation, studied for comparison, was similarly
increased (Figure 4d). This was of interest, as MRGPRX2- and FcεRI-elicited mast cell degranulation
pathways are unconnected, as reported by us previously [16].
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Figure 4. Short-term IL-33 primes pseudo-allergic/neurogenic and allergic mast cell (MC) degranulation.
(a,b) Net β-hexosaminidase release activated by the MRGPRX2 agonists C48/80 (10 µg/mL) or SP
(30 µmol/L) 30 min post-activation following 30 min priming with/out IL-33 in 14 independent
experiments, each using a separate MC preparation. Dots representing the same preparation are
interconnected. (c) MRGPRX2 protein expression at the cell surface after 30 min of IL-33 treatment.
Representative histograms for control and IL-33. Red: Isotype control. Blue: Receptor-specific antibody.
(d) Net β-hexosaminidase release activated by FcεRI-aggregation (AER-37, 0.1 µg/mL), given for
comparison and primed with IL-33 as above. Data are the mean ± SEM of 14 independent experiments.
(e) Representitive histograms showing FcεRI protein expression. *** p < 0.001, **** p < 0.0001.
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To assess whether the augmented secretory competence was due to rapid changes in receptor
expression, we analyzed MRGPRX2 and FcεRI on the cell surface after short-term exposure to IL-33.
IL-33 did not change either MRGPRX2 or FcεRI expression (Figure 4c,e), which indicated that increased
degranulation did not stem from altered receptor expression but was rather related to signaling.
Together, IL-33 primes for enhanced degranulation by the pseudo-allergic/neurogenic (and allergic)
route in skin MCs, and this effect is not caused by altered receptor expression.
3.4. Reinforced Degranulation by IL-33 Depends on p38
Considering the unchanged receptor expression, but positive effect of IL-33 on degranulation
triggered by both routes, we asked whether the increment was brought about by p38, JNK, or both.
To discriminate between the possibilities, we pretreated MCs with p38 or JNK inhibitor prior to the
addition of IL-33, and then exposed them to the secretagogues. The p38 inhibitor basically reversed the
priming effect of IL-33 in both routes (i.e., MRGPRX2- and FcεRI-mediated), while the JNK inhibitor
had no significant effect (Figure 5).
Conversely, neither of the inhibitors influenced degranulation in the absence of IL-33 (Figure S5),
indicating that the p38-specific inhibitor exclusively interfered with the increment resulting from
IL-33 action.
Together, IL-33 exerts its priming effect on pseudo-allergic/neurogenic and allergic degranulation
of skin-derived MCs by activating p38.
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Figure 5. IL-33 priming occurs in a p38-dependent manner. Cells were pretreated with the inhibitors
SB203580 (p38) or SP600125 (JNK) for 15 min, then with or without IL-33 for 30 min, and finally
stim lated by C48/80 (10 µg/mL), SP (30 µmol/L), or FcεRI aggregation (AER-37, 0.1 µg/mL). The
net release of β-hexosaminidase was determined (in %) and normalized to cells equally tre ted with
inhibitors, but not exposed to IL-33. Cells treated with inhibitors alone served as controls (the results
a giv n in Figure S5). The data are th ean ± SEM of seven indep ndent xperiments. * p < 0.05,
** p < 0.01.
4. Discussion
Survival and function of MCs in their natural habitat are regulated by an intricate network of
growth factors, and cell-cell- as well as cell-matrix interactions, together forming the MC-supportive
niche. In this regard, the microenvironment is not only crucial for the regulation of MC differentiation
as such, but it also (re)shapes functional programs of MCs after terminal maturation. IL-33 has gained
fame as a MC lineage-supportive and - odulating cytokine. It belongs to the IL-1 superfamily, and
acts as an alarmin and pro-inflammatory factor when it is released into the extracellular space upon
infection or cell injury [38–40]. Due to its inflammatory and Th2-skewing potential [41,42], IL-33 is
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critical in the induction and maintenance of allergic disorders, such as asthma, atopic dermatitis, and
allergic rhinitis [43–45]. Accordingly, it is found at increased levels in a variety of skin disorders [46–48],
and may also play a role in tumorigenesis [49].
MCs are among the primary target cells of IL-33 [50], also owing to their abundant expression
of the IL-33 receptor ST2 in comparison with a multitude of primary cells, as uncovered by the
comprehensive body-wide expression atlas FATOM5 [13]. IL-33 influences MC biology at various
levels and modulates their phenotype, synthetic capacity, and mediator release, but this occurs in a
MC-subset-dependent manner. For human skin MCs, we recently reported a yin-yang type response,
whereby MCs were numerically strengthened and endowed with greater histamine synthetic capacity,
while allergic degranulation elicited by FcεRI aggregation and FcεRI expression were attenuated when
cells were chronically exposed to the “alarmin” [24].
Whether the newer pseudo-allergic/neurogenic pathway may be modulated by IL-33 is unclear.
The receptor MRGPRX2 that is responsible for these reactions is confined to MCTC type MCs [1],
which are basically the only MC subset in human skin [51]. We therefore studied the modulation
of MRGPRX2-driven activation by IL-33, placing particular emphasis on the distinction between
short-term priming and long-term adaptation effects, and also addressed the mechanisms involved.
Ligands targeting MRGPRX2 are numerous and comprise C48/80, drugs like neuromuscular
blocking agents, fluoroquinolones, and icatibant, host defense peptides (e.g., cathelicidin), and
neuropeptides like SP [5,11,15,52,53]. Because of the large and still increasing number of secretagogues
acting by MRGPRX2 activation, the receptor has become the spotlight of MC research and is linked
to a number of diseases triggered by non-immunological MC activation, including injection-site
hypersensitivity reactions, chronic urticaria, atopic dermatitis, red man syndrome, periodontitis,
and drug anaphylaxis [1,3,5,12,15,53]. In particular, a bidirectional cross-talk between MCs and
sensory neurons is widely appreciated, and MCs can be found adjacent to peripheral nerve endings,
where they are involved in neurogenic inflammation. By acting as the receptor for a variety of
neuropeptides (including Substance P, VIP (Vasoactive intestinal peptide), somatostatin, cortistatin
and PACAP (pituitary adenylate cyclase-activating peptide) [1,5,11]), likely MRGPRX2 contributes
to neurogenic inflammation. In fact, it was recently demonstrated that MRGPRX2 (and its murine
equivalent) mediated mechanical and thermal hyperalgesia, as well as immune cell recruitment by
MC cytokine/chemokine release triggered by SP (Substance P) [54]. This is in accordance with another
report showing that intradermal injections of PACAP result in cytokine secretion promoting leukocyte
recruitment in a MC dependent fashion [55].
In our previous study, FcεRI-mediated degranulation was reduced in MCs from a majority of
skin donors and FcεRI expression was simultaneously reduced on long-term IL-33 exposure [24].
To discern IL-33’s role in MRGPRX2-triggered activation in the same setting (mimicking chronic
inflammation), the current study first focused on MC responsiveness to MRGPRX2-stimulation upon
long-term exposure to IL-33 and concomitant receptor expression. Surprisingly, chronic exposure
to IL-33 did not only reduce, but basically eliminated, the pseudo-allergic/neurogenic route in skin
MCs, and this was found equally with both MRGPRX2 ligands, namely SP and C48/80. Reduced
degranulation was associated with massive downregulation of receptor expression, indicating that
dampened stimulability was brought about by a lack of MRGPRX2 at the cell surface. At transcript
level, downregulation was already observable a few hours after contact with IL-33, suggesting a fairly
rapid mechanism of action.
Knowing that IL-33 activates JNK and p38 in skin-derived MCs [24] (see also Figure S3), we
employed pharmacological inhibitors and Accell®-mediated knockdown of the kinases as strategies to
elucidate the molecular underpinnings behind MRGPRX2 down-regulation. Surprisingly, along the
way, we found that JNK seemed a positive regulator of MRGPRX2 expression in its own right. In fact,
interference with JNK in the absence of IL-33 led to reduced MRGPRX2 expression. As a result of its
relative novelty, the network of signaling intermediates and transcription factors enabling MRGPRX2
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expression exclusively in MCTC-type MCs is currently unresolved. Its partial reliance on JNK can set
the stage for mechanistic studies into its regulation.
Paradoxically, IL-33-mediated downregulation of MRGPRX2 seemed to partially require the
same kinase, while the process was independent of p38 action. In fact, the negative effect of IL-33 on
MRGPRX2 expression was partially reversed after perturbation of JNK, as JNK silencing and IL-33
had no additive effects in terms of MRGPRX2 downregulation, but even conversely, the JNK-KD
and IL-33 combined caused a somewhat higher MRGPRX2 expression without reaching baseline
levels. Our study therefore highlights that the same kinase (JNK) can adopt opposing roles in the
presence versus absence of IL-33. Reasons behind this dichotomy are currently unknown but may be
associated with the strength of the JNK signal. In fact, steady-state activity of JNK is below detection by
western blot in skin-derived MCs (Figure S3), even though some phosphorylated JNK can be measured
by flow-cytometry, as shown by us recently [24]. This low activity may be sufficient to maintain
functionality of transcription factors that drive MRGPRX2 expression (or alternatively, keep negative
regulators at bay). IL-33 increases JNK phosphorylation, and this enhanced activity may now lead to
the phosphorylation of a widened (and/or altered) set of effectors to mediate downregulation of the
receptor. Interference with this latter aspect would partially reverse the effect of IL-33 without being
able to restore MRGPRX2 expression to steady-state levels, because of the still-lacking baseline function
of JNK. This is exactly what we have found. In this scenario, MCs may tune their JNK pathway to make
it perform distinct functions in different contexts. Dependence of the role of JNK upon the cellular
context has been reported, especially with regard to apoptosis versus survival decisions, as JNK has
been associated with both of these opposing processes [56].
The negative regulation of the pseudo-allergic/neurogenic route by long-term IL-33 is notable,
because SCF by itself dampens MRGPRX2 responsiveness and expression [16,19], so that on extended
exposure, IL-33 further augments the negative effect of SCF and does not reverse the positive effect of
SCF (as detected for the allergic route) [19,24,33].
The combined findings from our previous report [24] and this study indicate that long-term
IL-33 may yield effects reminiscent of long-term exposure to glucocorticoids, as reported recently by
Yamada and colleagues for murine CTMC [57]. In fact, we found reduced chymase mRNA, coupled
with increased histidine decarboxylase/histamine abundance [24], and a nearly abrogated MRGPRX2
pathway in this report, a triad of manifestations likewise detected for dexamethasone [57]. IL-33 and
glucocorticoids may thus employ overlapping strategies to cause this phenotypic switch in MCs.
We finally explored whether IL-33 impacts MRGPRX2-elicited exocytosis on short-term priming
and found that this was indeed the case. By direct comparison with FcεRI-triggered release, which
was similarly enhanced, we also disclosed what is, to our knowledge, the first mediator to uniformly
affect allergic and pseudo-allergic/neurogenic degranulation pathways.
In fact, potent MC-modulating factors thus far studied (SCF, IL-4, and retinoic acid) have shown a
clear-cut separation with opposite patterns of regulation, i.e., enhancing effects on the allergic route,
but concomitant suppression of the MRGPRX2 pathway [16,19,20]. IL-33 is thus the first cytokine to
support the MRGPRX2 route altogether.
On the other hand, priming effects of IL-33 on granule exocytosis, as such, have been reported
by different laboratories and for distinct types of cells. While most research found no effect on
degranulation of IL-33 alone, Kaur et al. showed that IL-33 could slightly degranulate MCs on its own,
but the extent was modest [58]. Conversely, more groups reported on increased allergic stimulability
in different types of MCs [25–28]. Increased degranulation by FcεRI-aggregation was likewise reported
for basophils [59,60]. In the current study, we confirmed that allergic degranulation is supported by
IL-33 also in skin-derived MCs (Figure 4).
In contrast to FcεRI-triggered degranulation, very little is known about if and how
MRGPRX2-driven responses may be regulated by IL-33. To our knowledge, only Cop et al.
studied MRGPRX2-triggered degranulation under the control of several cytokines, including IL-33,
in CD34+-derived MCs; they found no effect on the pseudo-allergic/neurogenic route but confirmed
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a supportive effect on allergic degranulation [25]. It remains unclear whether the different outcome
compared to our findings is due to the different signal strength mediated by MRGPRX2 in different
types of MCs or, more likely, whether it is the result of distinct signaling machineries contracted by
different MC subsets, including the degree of p38 activation. In skin MCs, as typical representatives of
the MCTC-type MC and prominent producers of MRGPRX2, the positive effect of IL-33 on MRGPRX2
function could be consistently detected for both ligands and (nearly) all MC preparations employed.
Together with previous studies, which reported priming effects of IL-33 on alternative MC
activation routes, including adenosine, C5a, and IgG [59,61], our present demonstration of strengthened
MRGPRX2 function implies that the mechanisms by which IL-33 increases acute MC responses may be
quite universal across degranulation-competent receptors beyond FcεRI.
Having found that receptor expression was unperturbed 30 min after IL-33 exposure, we assumed
that IL-33 signaling engaged in a positive cross-talk with signals transduced by MRGPRX2 (as well as
FcεRI). Examining whether JNK, p38, or both foster degranulation, we found that nearly the entire
priming effect of IL-33 depended on p38, and was abolished by SB203580 (p38 inhibitor), whereas JNK
played no apparent role. IL-33 is highly effective at p38 activation, and signal intensity may be key to
the strengthened degranulability of MCs. A further hint comes from the difference with SCF, which
dampens the MRGPRX2-driven route [16]. In fact, distinct signaling events are elicited by IL-33/ST2
vis-à-vis SCF/KIT in skin-derived MCs, as described recently: p38 activation uniquely occurs upon
IL-33 stimulation and is undetectable after SCF triggering [24]. In contrast, ERK1/2 and AKT activation
are limited to SCF and are below detection after IL-33.
The involvement of p38 is intriguing, because even though it forms part of the signaling cascade
elicited by FcεRI-aggregation, p38 has been more commonly associated with cytokine production
(especially TNF-α), lipid mediator generation, migration, proliferation, chemotaxis, and adhesion, but
not degranulation in the first place [62–70]. We confirmed a lacking effect of p38 on degranulation
elicited by the two routes in the absence of IL-33 (Figure S5), so p38 was only involved in the potentiation
by IL-33. This argues that p38 activation by IL-33 is qualitatively or quantitatively different from the
one triggered by FcεRI aggregation [71], or alternatively, that its activity needs to combine with other so
far undiscovered events specifically elicited by IL-33, but not by FcεRI (or MRGPRX2). Taken together,
this part of the study illuminated a novel regulatory role of the IL-33/p38 axis, which positively affected
granule exocytosis during acute pseudo-allergic/neurogenic and allergic responses alike.
Our combined results support the concept of a clear segregation between long- and short-term
effects exerted by IL-33. We recently reported that allergic skin MC degranulation is curbed when IL-33 is
chronically administered [24], while we found here that IL-33 has a priming effect on FcεRI-aggregation
when given acutely (Figure 4). We now report that the opposing roles of IL-33 apply even more so to
MRGPRX2-triggered activation, which is virtually abolished in a chronic setting, yet supported when
administered shortly before stimulation.
Our data reinforce the concept that MCs develop protection from overt and persistent IL-33 by
shutting down degranulation to avoid exaggerated responses and restore tissue homeostasis under
conditions of chronic inflammation. Conversely, an acute burst of IL-33 supports secretion, likely to
foster MC-dependent defense strategies. An anti-inflammatory character on prolonged exposure to
IL-33 is also highlighted by its resemblance with MC responses to sustained glucocorticoids [57].
The significance of the MC-IL-33 connection and necessity of MC protection against IL-33
hyperactivity is emphasized by the potent degradation of IL-33 by MC chymase released from skin
MCs during degranulation, together with histamine [72,73]. In fact, IL-33 is one of the fewer (among a
panel of) cytokines targeted for degradation by granule-associated proteases, suggesting a mechanism
of negative feedback control [72]. The importance of chymase-mediated degradation of IL-33 was also
found in vivo in an allergic airway inflammation model [74].
Along the same lines, a protective, anti-inflammatory function of the IL-33/ST2/MC axis has
been described by different studies, including limitation of inflammatory monocyte responses [61],
enhancement of regulatory T cells through enhanced IL-2 production [75,76], protection against airway
Cells 2019, 8, 341 13 of 17
hyperresponsiveness owing to PGE2 generation [77], and MC-dependent restoration of mucosal
healing [78].
Collectively, IL-33 functions as a double-edged cytokine in skin MCs, which highlights its
involvement in the tunable nature of MCs as mediators or suppressors of immune and inflammatory
responses [79].
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/8/4/341/s1,
Figure S1: Foreskin MCs downregulate the MRGPRX2 route upon long-term IL-33 treatment. Figure S2: Time
course of MRGPRX2 mRNA expression upon IL-33 treatment. Figure S3: JNK and p38 are phosphorylated upon
IL-33 administration. Figure S4: JNK knockdown (KD) efficiency. Figure S5: MC degranulation in the absence of
IL-33 priming does not depend on either JNK or p38 activity.
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